Adaptyv logo — The cloud lab for protein designers

Adaptyv

The cloud lab for protein designers

Founded 2020 Switzerland Lausanne, Switzerland 36 employees Series A Total: $9.13M Biotechnology, Pharmaceutical

General Information

Company Name Adaptyv
Founded Year 2020
Location Switzerland Lausanne, Switzerland
Employees 36
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Business Model B2B, SaaS, API
Revenue Model Usage Based, Service Fee, Subscription
Social

BounceWatch is an independent company data service, not affiliated with Adaptyv. To contact Adaptyv, visit adaptyvbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Adaptyv compare?

A PDF of Adaptyv and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Adaptyv soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Major Customer Win Oct 11, 2026

Adaptyv has secured Google DeepMind, validating proteins related to their new SynthID Bio model.

About Adaptyv

Adaptyv, founded in 2020, is spearheading innovation in the Biotechnology and Pharmaceutical industries from its headquarters in Switzerland. Known as "The cloud lab for protein designers," Adaptyv focuses on creating a next-generation protein foundry. This technology enables the synthesis and testing of custom-designed proteins, positioning the company at the forefront of advanced nanotechnology applications.

Recently, Adaptyv secured a Fr.6.40M Series A investment on 01 October 2025. The funding round was backed by notable investors such as byFounders, Founderful, ACE Ventures, and LongGame. The investment highlights strong market confidence in Adaptyv's potential to revolutionize protein design solutions.

For investors, Adaptyv represents a promising opportunity characterized by cutting-edge technology and robust financial backing, geared to address growing demands in biotechnology and pharmaceutical developments.

Business keywords: protein engineering, synthetic biology, nanofluidics, cell-free synthesis, protein foundry, nanotechnology, biotechnology innovation, protein design, next-gen biosystems, biological testing platforms, biotech research and development, molecular biology tools, protein synthesis, biotechnology platforms

Services & Products

Protein validation
Experimental data management
AI model integration for protein design
Automated assay execution
Comprehensive experimental data analysis

Target Customers

Protein design teams Biotech and pharmaceutical companies Research institutions focused on protein engineering Biopharmaceutical developers using AI

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Fr.6.40M 4
byFounders, Founderful +2
01 Oct 2025
Debt Financing Fr.100.00K 1
Fondation FIT
01 Jul 2023
Seed Fr.2.50M 11
Y Combinator, Rheingau Founders +9
01 Feb 2022
Grant $130.00K 1
Y Combinator
01 Aug 2021
Spinout Undisclosed 1
EPFL - Swiss Federal Institute of Technology in Lausanne
01 Jan 2020

Adaptyv Alternatives & Competitors

View All Alternatives
Adaptyv vs
Avenue Biosciences
Avenue Biosciences United States

Transforming protein biologics with groundbreaking high-throughput protein engineering.

Seed
23 employees
Biotechnology, Pharmaceutical
Adaptyv vs
Nuclera
Nuclera United Kingdom

Bring rapid protein access to your benchtop with eProtein Discovery

Series C
108 employees
Biotechnology, Life Sciences
Adaptyv vs
Synbio Technologies
Synbio Technologies United States

Changing the world, one sequence at a time.

25 employees
Biotechnology, Health Care

FAQ About Adaptyv

The cloud lab for protein designers
Adaptyv was founded in 2020.
Adaptyv is headquartered in Lausanne, Switzerland.
Adaptyv operates in Biotechnology and Pharmaceutical. Its work centres on protein engineering, synthetic biology, nanofluidics and cell-free synthesis. Its customers include Protein design teams, Biotech and pharmaceutical companies and Research institutions focused on protein engineering.
Adaptyv has a B2B, SaaS and API business model. Its revenue comes from Usage Based, Service Fee and Subscription.
Adaptyv has approximately 36 employees.
Adaptyv has completed 5 funding rounds, raising a total of $9.13M. The latest funding stage is Series A.
Adaptyv offers: Protein validation, Experimental data management, AI model integration for protein design, Automated assay execution, Comprehensive experimental data analysis.
Top alternatives and competitors to Adaptyv include Avenue Biosciences, Nuclera, Synbio Technologies, Synlife, Core Biogenesis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Adaptyv and Avenue Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Adaptyv, https://bouncewatch.com/company/adaptyv-biosystems, updated 22 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes